Advanced Tissue Sciences' skin replacement approved
This article was originally published in Clinica
Advanced Tissue Sciences has received approval from the FDA to market its Dermagraft-TC temporary skin replacement in the US. The substitute skin is intended for people who are severely burned and in need of wound covering until their own skin can be grafted. Advanced Tissue Sciences, based in La Jolla, California, estimates that nearly 5,500 people die and at least 51,000 are hospitalised for burn treatment in the US each year.
You may also be interested in...
AMAG outlines plans for retrospective real-world evidence studies, and possibly a new placebo-controlled trial with a primary endpoint of preterm birth <32 weeks, in a filing opposing the Center for Drug Evaluation and Research’s proposal to withdraw the drug.
The leading Korean pharma firm’s oral, third-generation EGFR-TKI is approved in the country, providing a new option for patients with advanced NSCLC and increasing hopes for global approvals given an ongoing global Phase III combination trial led by partner J&J.
DePuy Synthes expects its Velys robotic-assisted system to be cost-effective, easy-to-use and to be well-suited for use in ambulatory surgery centers.